

ARTWORK / PRINTPROOF APPROVAL FORM

Note : Text matter changes under highlights Recent major changes, Section no 6, Section no 13 and medication guide due to the IR letter received on dated 08 January 2026 and text matter changes under medication guide due to the SLC letter received on dated 15 January 2026.

1. Product: Ibandronate Sodium Tablets					
2. Country: USA		3. Packaging component: Professional Package insert			
4. No. of Colours: 1 Colour		5. Pantone Shade No.: Black			
6. Specification: 40 gsm Bible paper					
7. Machine Layout No.: NA		8. Dimensions: 545 (L) x 490 (W) mm			
9. Design / Style: NA		10. Item code No.: PM04341388			
11. Artwork has been made: Actual Size		12. Pharma code No.: 40872 mini			
13. Barcode/NDC no: NA		14. Supersedes Item code No: PM04340539			
15. Revision no: 02		16. File Name : D:\Regulatory Artwork\US\Ibandronate Sodium\07\Ibandronate Sodium leaflet PM04341388.cdr			
Approved By:		17. Location: Baddi			
PRD	MKT	MEDICAL/RAD	QC	PRODN	QA

Note: 1. To follow overleaf checklist for approval of Artwork / Print proof.

Instructions to Vendor :

1. Before processing, please ensure First pull out / Commercial supply should match with approved Artwork with respect to Design, Size, Fonts & Text.
2. Print proof to represent full printing area with Station Numbers.

FRM/CQA/021/04-01

Reason for revision :	Item code	Artwork Send for Printing Date	Artwork Implementation Date
1) New Artwork for USA	PM04335091	06/12/2024	31/01/2025
2) Changes done as per Safety Labeling Changes Notification update section- Recent major changes, section 5, section 6 and medication guide.	PM04340539	9/12/2025	
3) Text matter changes under highlights Recent major changes, Section no 6, Section no 13 and medication guide due to the IR letter received on dated 08 January 2026 and text matter changes under medication guide due to the SLC letter received on dated 15 January 2026.	PM04341388		